(Q36396219)

13 August 2017

Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection (English)

1 reference

13 August 2017

1 reference

1 reference

Jacob Lalezari

1

1 reference

13 August 2017

David Asmuth

2

1 reference

13 August 2017

Arnaldo Casiró

3

1 reference

13 August 2017

Hugo Vargas

4

1 reference

13 August 2017

Shannon Lawrence

5

1 reference

13 August 2017

Gloria Dubuc-Patrick

6

1 reference

13 August 2017

Jie Chen

7

1 reference

13 August 2017

Joseph McCarville

8

1 reference

13 August 2017

Keith Pietropaolo

9

1 reference

13 August 2017

Xiao-Jian Zhou

10

1 reference

13 August 2017

John Sullivan-Bólyai

11

1 reference

13 August 2017

Douglas Mayers

12

1 reference

13 August 2017

language of work or name

English

0 references

publication date

15 October 2012

1 reference

Antimicrobial Agents and Chemotherapy

13 August 2017

1 reference

13 August 2017

56

1 reference

13 August 2017

12

1 reference

13 August 2017

6372-6378

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

Boceprevir for untreated chronic HCV genotype 1 infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

Resistance to direct antiviral agents in patients with hepatitis C virus infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

On the cusp of change: new therapeutic modalities for HCV.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3497200

21 September 2018

Identifiers

DOI

10.1128/AAC.01521-12

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

23070151

1 reference